Proton-pump inhibitors adverse effects: A review of the evidence and position statement by the Sociedad Española de Patología Digestiva

Revista Espanola de Enfermedades Digestivas

Volumn 108, Issue 4, 2016, Pages 207-224

  de la Coba, Cristóbal ^a,b   Argüelles Arias, Federico ^c   Martín De Argila, Carlos ^d   Júdez, Javier ^a   Linares, Antonio ^e   Ortega Alonso, Aida ^f,g   Rodríguez, Enrique ^d   Rodríguez Téllez, Manuel ^c   Vera, Isabel ^h   Aguilera, Lara ^d   Álvarez, Ángel ⁱ   Andrade, Raúl J ^f   Bao, Fidencio ^j   Castro, Manuel ^k   Giganto, Froilán ^l  

^a SEPD   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Sanatorio Nuestra Señora de Covadonga   (Spain)

^f Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

ⁱ UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^j Hospital de San Eloy   (Spain)

^k HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

Adverse effects; Guidelines as topic; Position statement; Proton pump inhibitors; SEPD

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; THIENOPYRIDINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CYANOCOBALAMIN DEFICIENCY; DRUG INDICATION; DRUG INDUCED DISEASE; ELECTROLYTE DISTURBANCE; FRACTURE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INTESTINE INFECTION; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; EVIDENCE BASED MEDICINE; FRACTURES, BONE; INFECTION; LIVER CIRRHOSIS; NERVOUS SYSTEM DISEASES;

DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; HUMANS; INFECTION; LIVER CIRRHOSIS; MAGNESIUM DEFICIENCY; NERVOUS SYSTEM DISEASES; PROTON PUMP INHIBITORS;

EID: 84976444868     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.17235/reed.2016.4232/2016     Document Type: Article

References (173)

1. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors-What the practising physician needs to know. Drugs 2003;63:2739-54.
2. García del Pozo J. Estudio de utilización de antiulcerosos en España (2000-2008). Inf Ter Sist Nac Salud 2009;33:49-54.
3. Ministerio de Sanidad. Subgrupos ATC y Principios activos de mayor consumo en el Sistema Nacional de Salud en 2010.Inf Ter Sist Nac Salud 2010;35:124-8.
4. Ponce J, Esplugues JV. Rationalizing the use of PPIs: An unresolved matter. Rev Esp Enferm Dig 2013;105:121-4. DOI: 10.4321/S1130-01082013000300001
5. Simo Minana J. Use of prescription drugs in Spain and Europe. Aten Primaria. 2012;44:335-47.
6. Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005;21:1203-9. DOI: 10.1111/j.1365-2036.2005.02454.x
7. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561-8. DOI: 10.2169/internalmedicine.49.4064
8. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23:116-7.
9. de Burgos Lunar C, Novo del Castillo S, Llorente Diaz E, et al. Study of prescription-indication of proton pump inhibitors. Rev Clin Esp 2006;206:266-70.
10. Martin-Echevarria E, Pereira Julia A, Torralba M, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig 2008;100:76-81.
11. Batuwitage BT, Kingham JGC, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8. DOI: 10.1136/pgmj.2006.051151
12. Ahrens D, Chenot J-F, Behrens G, et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010;66:1265-71. DOI: 10.1007/s00228-010-0871-9
13. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Brit J Clin Pharmacol 2010;69:543-52. DOI: 10.1111/j.1365-2125.2010.03628.x
14. Villamanan E, Ruano M, Lara C, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig 2015;107:652-8.
15. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010;5:288-97.
16. Ahrens D, Behrens G, Himmel W, et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract 2012; 66:767-73. DOI: 10.1111/j.1742-1241.2012.02973.x
17. Ponce Romero M, Berenguer Lapuerta J. Current indications for proton pump inhibitors. Rev Clin Esp 2003;203:136-8.
18. Grupo de trabajo Sector Zaragoza I Salud. Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos. Guía de Práctica Clínica. Zaragoza: Guía Salud; 2012.
19. Product Characteristics. Spanish Agency of Medicines and Medical Devices.
20. Arroyo Villarino M, Lanas Arbeloa A. Gastroenteropatía por AINE. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011. p. 123-31.
21. Pérez Gisbert J, Martín Argila C. Úlcera péptica e infección por Helicobacter pylori. En: Ponce García J, editor. Asociación Española de Gastroenterología. Tratamiento de las enfermedades gastroenterológicas. Barcelona: Elsevier; 2011. p. 109-21.
22. Sung JJY, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding-a randomized trial. Ann Intern Med 2009;150:455-64. DOI: 10.7326/0003-4819-150-7-200904070-00105
23. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers-a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-62. DOI: 10.1001/jamainternmed.2014.4056
24. Yen H-H, Yang C-W, Su W-W, et al. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012;12:66. DOI: 10.1186/1471-230X-12-66
25. Pérez-Gisbert J, Calvet X, Ferrandiz J, et al. Clinical practice guideline on the management of patients with dyspepsia. Update 2012. Gastroenterol Hepatol 2012;35:725.e1-38.
26. Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:1066-78.
27. Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:13-22.e1. DOI: 10.1016/j.cgh.2015.07.041
28. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 2015; (online first): pii: gutjnl-2015-310991. Accesible en: http://www.ncbi.nlm.nih.gov/pubmed/26685124 DOI: 10.1136/gutjnl-2015-310991
29. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 2006;55:1056-7. DOI: 10.1136/gut.2006.094912
30. Stabler SP. Vitamin B-12 Deficiency. N Engl J Med 2013;368:149-60.
31. Jung SB, Nagaraja V, Kapur A, et al. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J 2015;45:409-16.
32. Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B-12 deficiency. JAMA 2013;310:2435-42. DOI: 10.1001/jama.2013.280490
33. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 2008;9:162-7. DOI: 10.1016/j.jamda.2007.10.004
34. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B-12 deficiency in older adults. J Clin Epidemiol 2004;57:422-8. DOI: 10.1016/j.jclinepi.2003.08.015
35. Force RW, Meeker AD, Cady PS, et al. Increased vitamin B-12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37:490-3.
36. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994;120:211-5. DOI: 10.7326/0003-4819-120-3-199402010-00006
37. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol 2001;54:531-4. DOI: 10.1016/S0895-4356(00)00340-1
38. Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406. DOI: 10.1111/j.1365-2036.1992.tb00553.x
39. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B-12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-30. DOI: 10.1016/S0002-9343(98)00087-4
40. Rozgony NR, Fang C, Kuczmarski MF, et al. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010;29:87-99. DOI: 10.1080/01639360903574734
41. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92. DOI: 10.1097/00004836-199206000-00005
42. Schenk BE, Festen HPM, Kuipers EJ, et al. Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-5. DOI: 10.1046/j.1365-2036.1996.27169000.x
43. Den Elzen WPJ, Groeneveld Y, De Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27:491-7. DOI: 10.1111/j.1365-2036.2008.03601.x
44. ter Heide H, Hendriks HJE, Heijmans H, et al. Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B-12 deficiency? J Pediatr Gastroenterol Nutr 2001;33:342-5. DOI: 10.1097/00005176-200109000-00023
45. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: A retrospective review of safety. Dig Dis Sci 2008;53:385-93. DOI: 10.1007/s10620-007-9880-7
46. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-21. DOI: 10.1111/j.1365-2036.2008.03658.x
47. Long AN, Atwell CL, Yoo W, et al. Vitamin B-12 deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care 2012;35:E84-E. DOI: 10.2337/dc12-0980
48. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015;41:1162-74. DOI: 10.1111/apt.13194
49. Bellou A, AimoneGastin I, DeKorwin JD, et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med 1996;240:161-4. DOI: 10.1046/j.1365-2796.1996.20846000.x
50. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015;265:419-28. DOI: 10.1007/s00406-014-0554-0
51. Rajabally YA, Jacob S. Neuropathy associated with lansoprazole treatment. Muscle Nerve 2005;31:124-5. DOI: 10.1002/mus.20155
52. Sellapah S. An unusual side effect of omeprazole: case report. Br J Gen Pract 1990;40:389.
53. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013;83:692-9. DOI: 10.1038/ki.2012.452
54. Sumukadas D, McMurdo MET, Habicht D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am Geriatr Soc 2012;60:392-3. DOI: 10.1111/j.1532-5415.2011.03808.x
55. Gau J-T, Yang Y-X, Chen R, et al. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012;21:553-9. DOI: 10.1002/pds.3224
56. Sharara AI, Chalhoub JM, Hammoud N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol 2016;14:317-21. DOI: 10.1016/j.cgh.2015.10.012
57. Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012;46:93-114. DOI: 10.1097/MCG.0b013e3182333820
58. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-6. DOI: 10.1056/NEJMc066308
59. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Ref. MUH (FV), 27/2011. Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUso-Humano/seguridad/2011/docs/NI-MUH_27-2011.pdf. [visitado 23/12/15]
60. FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Washington, DC: US. Food and Drug Administration; 2011. Accesible en: http://www.fda.gov/Drugs/DrugSafety/ucm213206.htm.
61. Administration TG. Risk of hypomagnesaemia with proton pump inhibitors. Medicines Safety Update Vol 2, Number 3. Australian Prescriber 2011;34:81. Accesible en: https://www.tga.gov.au/publicationissue/medicines-safety-update-vol-2-no-3-june-2011
62. Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-analysis. PLoS One 2014;9:e112558. DOI: 10.1371/journal.pone.0112558
63. Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013;47:773-80. DOI: 10.1345/aph.1R556
64. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015;37:1237-41. DOI: 10.3109/0886022X.2015.1057800
65. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H-2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. DOI: 10.1007/s00223-006-0021-7
66. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53. DOI: 10.1001/jama.296.24.2947
67. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008;179:319-26. DOI: 10.1503/cmaj.071330
68. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9. DOI: 10.1592/phco.28.8.951
69. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9. DOI: 10.1007/s00223-008-9170-1
70. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9. DOI: 10.1007/s00223-008-9188-4
71. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101. DOI: 10.1053/j.gastro.2010.03.055
72. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women results from the women’s health initiative. Arch Intern Med 2010;170:765-71. DOI: 10.1001/archinternmed.2010.94
73. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based casecontrol study. Osteoporos Int 2011;22:903-10.DOI: 10.1007/s00198-010-1337-8
74. Reyes C, Formiga F, Coderch M, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 2013;52:557-61. DOI: 10.1016/j.bone.2012.09.028
75. Cea Soriano L, Ruigomez A, Johansson S, et al. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 2014;34:570-81. DOI: 10.1002/phar.1410
76. Ding J, Heller DA, Ahern FM, et al. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 2014;94:597-607. DOI: 10.1007/s00223-014-9855-6
77. van der Hoorn MMC, Tett SE, de Vries OJ, et al. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 2015;81:675-82. DOI: 10.1016/j.bone.2015.08.024
78. Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a populationbased study. Osteoporos Int 2015; 26: 2501-7. DOI: 10.1007/s00198-015-3168-0
79. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Br Med J 2012;344. DOI: 10.1136/bmj.e372
80. Adams AL, Black MH, Zhang JL, et al. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol 2014;24:286-90.
81. Lewis JR, Barre D, Zhu K, et al. Long-Term proton pump inhibitor therapy and falls and fractures in elderly women: A prospective cohort study. J Bone Miner Res 2014;29:2489-97. DOI: 10.1002/jbmr.2279
82. Moberg LME, Nilsson PM, Samsioe G, et al. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 2014;78:310-5. DOI: 10.1016/j.maturitas.2014.05.019
83. Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:1131-6. DOI: 10.1002/pds.2026
84. Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013;24:1161-8.
85. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998-1004. DOI: 10.1001/archinternmed.2011.20
86. de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009;20:1989-98. DOI: 10.1007/s00198-009-0891-4
87. Itoh S, Sekino Y, Shinomiya K-I, et al. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 2013;31:206-11. DOI: 10.1007/s00774-012-0406-9
88. Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013;48:1016-22. DOI: 10.1007/s00535-012-0722-9
89. Eom C-S, Park SM, Myung S-K, et al. Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med 2011;9:257-67. DOI: 10.1370/afm.1243
90. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-18. DOI: 10.1038/ajg.2011.113
91. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: A meta-analysis of 11 international studies. Am J Med 2011;124:519-26.
92. Yang S-D, Chen Q, Wei H-K, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med 2015; 8:4899-910.
93. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 2015. Accesible en: http://www.ncbi.nlm.nih.gov/pubmed/26462494
94. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43-53. DOI: 10.2165/00002512-199812010-00005
95. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60. DOI: 10.1001/archinternmed.2009.357
96. Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: A populationbased cohort study. J Bone Miner Res 2014;29:268-74. DOI: 10.1002/jbmr.2011
97. O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am J Med 2005;118:778-81. DOI: 10.1016/j.amjmed.2005.02.007
98. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. J Bone Miner Res 2010;25:2205-11. DOI: 10.1002/jbmr.108
99. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: A population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012;107:1361-9. DOI: 10.1038/ajg.2012.200
100. Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 2012;32:67-79. DOI: 10.1002/PHAR.1007
101. Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: A SWAN Cohort Study. J Bone Miner Res 2015;30:232-9. DOI: 10.1002/jbmr.2344
102. Jo Y, Park E, Ahn SB, et al. A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: A prospective randomized study. Gut Liver 2015;9:607-14. DOI: 10.5009/gnl14135
103. Moayyedi P, Yuan Y, Leontiadis G, et al. Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy-a 2013 update. Can J Gastroenterol 2013;27:593-5. DOI: 10.1155/2013/321379
104. Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol 2014;12:414-23. DOI: 10.1007/s11938-014-0030-y
105. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56. DOI: 10.1111/j.1572-0241.2007.01275.x
106. Freeman R, Dabrera G, Lane C, et al. Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella Mikawasima in the UK, 2013. Epidemiol Infect 2015:1-8. DOI: 10.1017/S0950268815002332
107. Wu H-H, Chen Y-T, Shih C-J, et al. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: A nested case-control study. Clin Infect Dis 2014;59:1554-8. DOI: 10.1093/cid/ciu628
108. García Rodríguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418-23.
109. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 2012;107:1011-9. DOI: 10.1038/ajg.2012.108
110. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol 2012;107:1001-10.DOI: 10.1038/ajg.2012.179
111. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and clostridium difficile infection in a metaanalysis. Clin Gastroenterol Hepatol 2012;10:225-33. DOI: 10.1016/j.cgh.2011.09.030
112. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015;175:784-91. DOI: 10.1001/jamainternmed.2015.42
113. FDA Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Washington, DC: US. Food and Drug Administration; 2012. Accesible en: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.
114. Laheij RJF, Sturkenboom M, Hassing RJ, et al. Risk of communityacquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60. DOI: 10.1001/jama.292.16.1955
115. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia-A populationbased case-control study. Arch Intern Med 2007;167:950-5. DOI: 10.1001/archinte.167.9.950
116. Sarkar M, Hennessy S, Yang Y-X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-8.
117. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-77. DOI: 10.1111/j.1365-2036.2010.04284.x
118. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012;5:337-45. DOI: 10.1586/ecp.12.20
119. Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10:e0128004. DOI: 10.1371/journal.pone.0128004
120. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310-9. DOI: 10.1503/cmaj.092129
121. Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013;28:223-30. DOI: 10.1007/s11606-012-2211-5
122. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014;63:552-8. DOI: 10.1136/gutjnl-2013-304738
123. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9. DOI: 10.1124/dmd.109.029132
124. Simon N, Finzi J, Cayla G, et al. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol 2015;71:1059-66. DOI: 10.1007/s00228-015-1882-3
125. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009;43:1266-74. OI: 10.1345/aph.1M051
126. Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-60. DOI: 10.1016/j.jacc.2007.06.064
127. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17.
128. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97. DOI: 10.1016/S0140-6736(09)61525-7
129. Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor insights from the platelet inhibition and patient outcomes trial. Circulation 2012;125:978-86. DOI: 10.1161/CIRCULATIONAHA.111.032912
130. Siller-Matula JM, Jilma B, Schroer K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624-41. DOI: 10.1111/j.1538-7836.2010.04049.x
131. Hulot J-S, Collet J-P, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-offunction allele or proton pump inhibitor coadministration a systematic meta-analysis. J Am Coll Cardiol 2010;56:134-43. DOI: 10.1016/j.jacc.2009.12.071
132. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31:810-23. DOI: 10.1111/j.1365-2036.2010.04247.x
133. Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis. Int J Cardiol 2013;167:965-74. DOI: 10.1016/j.ijcard.2012.03.085
134. European Medicines Agency. Public statement: Interaction between clopidogrel and proton pump inhibitors. 2009; (29 may). Accesible en: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409.pdf [visitado 23/12/15]
135. European Medicines Agency. Public statement: Interaction between clopidogrel and proton pump inhibitors (update). 2010; (17 mar). Accesible en: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2010/03/WC500076346.pdf [visitado 23/12/15]
136. Food and Drug Administration. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole (27 oct). 2010.Accesible en: http://www.fda.gov/Drugs/DrugSafety/ucm231161.htm. [visitado 23/12/15]
137. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Interacción de clopidogrel con los inhibidores de la bomba de protones: actualización de la información y recomendaciones de uso (Nota informativa). 2010.Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2010/docs/NI_2010-04_clopidogrel.pdf. [visitado 23/12/15]
138. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011;27:208-21. DOI: 10.1016/j.cjca.2010.12.033
139. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:1708-13,13a-13b. DOI: 10.1093/eurheartj/eht042
140. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One 2015;10.DOI: 10.1371/journal.pone.0124653
141. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009;7:1292-8. DOI: 10.1016/j.cgh.2009.05.021
142. Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2015;2:e000248-e. DOI: 10.1136/openhrt-2015-000248
143. Sherwood MW, Melloni C, Jones WS, et al. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc 2015;4. DOI: 10.1161/JAHA.115.002245
144. Weisz G, Smilowitz NR, Kirtane AJ, et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: The ADAPT-DES Study. Circ Cardiovasc Interv 2015;8.
145. Nicolau JC, Bhatt DL, Roe MT, et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J 2015;170:683-94. e3. DOI: 10.1016/j.ahj.2015.05.017
146. Hsieh C-F, Huang W-F, Chiang Y-T, et al. Effects of clopidogrel and proton pump inhibitors on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: A Nationwide Cohort Study. PLoS One 2015;10:e0135915. DOI: 10.1371/journal.pone.0135915
147. Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome-a systematic review. Heart 2013;99:520-7. DOI: 10.1136/heartjnl-2012-302371
148. Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes 2015;8:47-55. DOI: 10.1161/CIRCOUTCOMES.114.001177
149. Berger PB. Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn! Circ Cardiovasc Qual Outcomes 2015;8:6-7. DOI: 10.1161/CIRCOUTCOMES.114.001586
150. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301:2120-8. DOI: 10.1001/jama.2009.722
151. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent clostridium difficile infection. Arch Intern Med 2010;170:772-8. DOI: 10.1001/archinternmed.2010.73
152. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-4. DOI: 10.1038/ajg.2009.80
153. Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res 2015;14:7490-501. DOI: 10.4238/2015.July.3.25
154. Campbell MS, Obstein K, Reddy KR, et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008;53:394-8. DOI: 10.1007/s10620-007-9899-9
155. Trikudanathan G, Israel J, Cappa J, et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011;65(6):674-8. DOI: 10.1111/j.1742-1241.2011.02650.x
156. Choi EJ, Lee HJ, Kim KO, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011;46:616-20. DOI: 10.3109/00365521.2011.551891
157. Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012;10:422-7. DOI: 10.1016/j.cgh.2011.11.019
158. Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis. J Gastroenterol Hepatol 2013;28:235-42. DOI: 10.1111/jgh.12065
159. de Vos M, De Vroey B, Garcia BG, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int 2013;33:1316-23. DOI: 10.1111/liv.12210
160. Miura K, Tanaka A, Yamamoto T, et al. Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosis. Intern Med 2014;53:1037-42. DOI: 10.2169/internalmedicine.53.2021
161. Ratelle M, Perreault S, Villeneuve JP, et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol 2014;28:330-4. DOI: 10.1155/2014/751921
162. Min YW, Lim KS, Min BH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther 2014;40:695-704. DOI: 10.1111/apt.12875
163. Mandorfer M, Bota S, Schwabl P, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One 2014;9: e110503. DOI: 10.1371/journal.pone.0110503
164. O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:753-9. e1-2.
165. Terg R, Casciato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. J Hepatol 2015;62:1056-60. DOI: 10.1016/j.jhep.2014.11.036
166. Chang SS, Lai CC, Lee MT, et al. Risk of spontaneous bacterial peritonitis associated with gastric Acid suppression. Medicine (Baltimore) 2015;94:e944. DOI: 10.1097/MD.0000000000000944
167. Kwon JH, Koh S-J, Kim W, et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2014;29:775-81. DOI: 10.1111/jgh.12426
168. Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of betablockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 2015;35:362-9. DOI: 10.1111/liv.12593
169. van Vlerken LG, Huisman EJ, van Hoek B, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation 2012;42:760-7. DOI: 10.1111/j.1365-2362.2011.02643.x
170. Dultz G, Piiper A, Zeuzem S, et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther 2015;41:459-66. DOI: 10.1111/apt.13061
171. Emre Y, Mesut S, Aylin Y, et al. Adverse drug reactions due to drugdrug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf 2015. Accesible en: http://www.ncbi.nlm.nih.gov/pubmed/26635063
172. Honer Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clin Infect Dis 2015. Accesible en: http://www.ncbi.nlm.nih.gov/pubmed/26611779
173. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176: 238-46.